跳至主要内容
临床试验/NCT00534807
NCT00534807撤回1 期

Effect of Rifampin on the Pharmacokinetics of Intravenous (IV) Vinflunine in Subjects With Advanced Cancer

Bristol-Myers Squibb2 个研究点 分布在 1 个国家开始时间: 2007年9月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
撤回
发起方
试验地点
2
主要终点
The Primary Outcome Measure of the effect of rifampin on the pharmacokinetics (PK) of intravenous (IV) vinflunine will be determined from the PK measurements

研究概览

简要总结

The purpose of this study is to test how vinflunine interacts with rifampin in the human body

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Cancer unresponsive to previous treatment
  • Consent for genetic samples

排除标准

  • Cancer of the blood
  • Spread of cancer to the brain
  • Moderate or severe nerve damage
  • Low white blood cell counts and platelet counts
  • Inadequate liver or kidney function
  • Prior treatment with vinflunine
  • Use of certain medications that might interfere with the metabolism of vinflunine

结局指标

主要结局

The Primary Outcome Measure of the effect of rifampin on the pharmacokinetics (PK) of intravenous (IV) vinflunine will be determined from the PK measurements

时间窗: taken during Cycle 2 of study treatment, at approximately 4 weeks after the start of study treatment

次要结局

  • The Secondary Outcome Measures of the safety and tolerability of vinflunine when administered alone and with rifampin(determined after 2 complete 21-day Cycles of study treatment, at approximately 6 weeks after the start of study treatment)

研究者

发起方
Bristol-Myers Squibb
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验